| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Topline Data Readout example | Phase 1/2 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Topline Data Readout example | Phase 1/2 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Topline Data Readout example | Phase 1/2 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Pyxis Oncology, Inc.$2.67
+0.03 (+1.14%)
D 30Pipeline Score Richly Valued Pharma · Commercial
Market Cap
124.18 M
EPS
-1.30
P/E Ratio
-
Value Trade
304.38 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
19.98 M
Operating CF
-26.00 M
Total Assets
64.30 M
Total Liabilities
33.03 M
Equity
31.27 M
D/E Ratio
12,345
-11.31 %
Week
13.29 %
1 Month
28.95 %
3 Month
-56.54 %
6 Month
-89.68 %
5 Year
-89.68 %
All Time
Cash Data
Cash Position
41.02 M
Monthly Burn
8.67 M
Runway
2.8 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
853.13 K
52 Week Range
0.97 - 5.55
% held by Insiders
18.32 %
% held by Institutions
42.66 %
Enterprise Value
99.94 M
Total Shares
63.36 M
Short %
6.3 %
Float Shares
36.37 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pyxis Oncology, Inc.
231Total events
3Upcoming
51Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 3
Event history 228
Q3 2026
◆Topline Readoutmicvotabart pelidotinClinical Data
Updated data from Phase 1/2 combination study expected 2H 2026
recurrent/metastatic head and neck squamous cell carcinoma and other tumor typessource ↗
Jun 4, 2026
Jun 2026
◆Topline Readoutmicvotabart pelidotinClinical Data
Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC
2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinomasource ↗
May 19, 2026
◆Oral PresentationPresentation
RBC Capital Markets Global Healthcare Conference fireside chat
May 7, 2026
Apr 21, 2026
◆Poster PresentationMICVOPresentation
Poster presentation of preclinical data for maMICVO in HNSCC at AACR 2026
head and neck squamous cell carcinoma (HNSCC)source ↗
Q2 2026
◆Timing GuidanceMICVOPresentation
Updated data from Phase 1/2 combination dose escalation study of MICVO + pembrolizumab in 1L/2L+ R/M HNSCC
recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumorssource ↗
Q2 2026
◆Topline ReadoutMICVOClinical Data
Updated MICVO Phase 1 monotherapy data in 2L+ R/M HNSCC
2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinomasource ↗
Apr 2026
▲Poster PresentationMICVOPresentation
Presented new preclinical data at AACR 2026 supporting MICVO as monotherapy and in combination with pembrolizumab
Head and Neck Squamous Cell Carcinomasource ↗
Drug Pipeline Intelligence
D30
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 34%
Micro Cap (rank 603 of 912)
Percentile RankPyxis Oncology, Inc. faces pipeline headwinds (30/100), with $148M risk-adjusted pipeline value, led by PYX-201 in Advanced Solid Tumors (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PYX-201 Small molecule | Solid Tumor | Phase 1 | NCT05720117 | 10% | $101M | RECRUITING | 330 | VERY_FAST | C (42) | Jun 30, 2028 | MODERATE_RISK | MEDIUM Jun 30, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
micvotabart pelidotin Fast Track | recurrent/metastatic head and neck squamous cell carcinoma | Phase 1 | 2026-03-23 | monotherapy: confirmed objective response rate 46%, disease control rate 92%, n 13; combination: confirmed objective response rate 71%, disease control rate 100%, n 7 Read More | Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Read More | |
micvotabart pelidotin Fast Track | recurrent/metastatic head and neck squamous cell carcinoma | Phase 1 | 2026-03-23 | monotherapy: confirmed objective response rate 46%, disease control rate 92%, n 13; combination: confirmed objective response rate 71%, disease control rate 100%, n 7 Read More | Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Read More | |
micvotabart pelidotin Fast Track | recurrent/metastatic head and neck squamous cell carcinoma | Phase 1 | 2026-03-23 | monotherapy: confirmed objective response rate 46%, disease control rate 92%, n 13; combination: confirmed objective response rate 71%, disease control rate 100%, n 7 Read More | Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PYXS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PYXS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PYXS▲ +5.2%on this news
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
Pyxis Oncology has announced a private placement financing expected to raise up to $114 million to support its lead program, MICVO. The financing will extend the company's cash runway into the second quarter of 2027, allowing for further clinical development and patient follow-up. Updated data from ongoing studies is anticipated in late 2026.
Read more →PYXS▼ -15.6%on this news· ran to -27% by day 3
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck
Pyxis Oncology has reported its first quarter 2026 financial results, highlighting advancements in its MICVO clinical program. Key clinical data updates are projected for mid-2026 and the second half of 2026, focusing on monotherapy and combination therapies for recurrent/metastatic head and neck cancer. The company also presented promising preclinical data at the AACR Annual Meeting 2026, indicating potential efficacy of MICVO. However, it continues to face financial challenges, with a reported net loss of $23.3 million in the quarter.
Read more →PYXSPyxis Oncology to Participate in Upcoming Investor Conferences
Pyxis Oncology, Inc. has announced its participation in several forthcoming investor conferences, including the RBC Capital Markets Global Healthcare Conference, Stifel Virtual Oncology Forum, and Jefferies Global Healthcare Conference. Management will engage in fireside chats to discuss the company's progress and its lead candidate, micvotabart pelidotin (MICVO), which is in clinical trials for treating difficult-to-treat cancers. This engagement aims to enhance investor awareness and support for Pyxis's innovative therapeutic developments.
Read more →PYXSPyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
Pyxis Oncology has appointed Nelson Azoulay as Chief Business Officer, bringing over 15 years of experience in corporate strategy and business development in the biopharma industry. His expertise in antibody-drug conjugates will be instrumental as he leads the corporate development strategy and pursues opportunities to advance the company’s lead clinical asset, MICVO. Both the company and Azoulay expressed excitement about addressing unmet needs in treating head and neck cancer, particularly through clinical milestones expected in the near future.
Read more →PYXSPyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
Pyxis Oncology announced new preclinical data demonstrating the anti-tumor efficacy of maMICVO, a mouse analog of MICVO, in a head and neck squamous cell carcinoma (HNSCC) model. The data indicated that maMICVO not only inhibited tumor growth when used alone but also worked synergistically with anti-PD-1 to achieve greater tumor control. These findings support the ongoing clinical development of MICVO as both a monotherapy and a combination treatment for R/M HNSCC patients. The new data will be presented at the AACR Annual Meeting 2026 in San Diego.
Read more →PYXSPyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Pyxis Oncology has completed target enrollment in its Phase 1 study of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell carcinoma. The company reported positive preliminary data, including a 46% confirmed objective response rate for MICVO as monotherapy. Financial results for 2025 showed a net loss of $79.6 million, with revenues declining to $13.9 million. The company expects to report updated data from ongoing studies in mid and late 2026.
Read more →PYXSPyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
Pyxis Oncology has appointed Thomas Civik as Interim CEO following the departure of Lara S. Sullivan. Civik, a seasoned biotechnology executive, aims to maintain leadership continuity while the Board searches for a permanent CEO. The company remains focused on advancing its lead program, micvotabart pelidotin (MICVO), in ongoing clinical trials.
Read more →PYXS▼ -48.7%on this news· ran to -68% by day 3
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma • 46% confirmed objective response rate (ORR) and 92% dise
Pyxis Oncology has announced promising preliminary Phase 1 data for its antibody-drug conjugate, micvotabart pelidotin (MICVO), in the treatment of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The data show a 46% confirmed objective response rate (ORR) for MICVO as monotherapy and a 71% confirmed ORR when combined with KEYTRUDA. The drug demonstrated a 92% disease control rate and is well-tolerated among treated patients. Future updates from ongoing trials are anticipated in mid-2026 and the second half of 2026.
Read more →PYXS▲ +7%on this newsshared move
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
Pyxis Oncology has provided a business update and reported its financial results for Q3 2025. The company anticipates preliminary data from its Phase 1 studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma by the end of 2025. The updates include insights from recent presentations at major oncology conferences, emphasizing the potential of MICVO as a treatment option.
Read more →PYXS▼ -6.4%on this news
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
Pyxis Oncology will present translational data on micvotabart pelidotin (MICVO) at ESMO 2025 and AACR-NCI-EORTC conferences. The data highlights MICVO's unique mechanism of action, which includes direct tumor cell killing and immune activation. The findings support ongoing clinical studies, particularly in head and neck squamous cell carcinoma.
Read more →PYXS▲ +31.6%on this newsshared move
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
Pyxis Oncology has appointed Alex Kane as Senior Vice President of Investor Relations and Capital Markets. With 20 years of experience in the life sciences sector, Kane previously worked at Guggenheim Securities and has held senior roles at other biotech firms. His expertise is expected to support Pyxis Oncology's clinical programs and investor engagement.
Read more →PYXSPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pyxis Oncology has granted stock options to seven new employees as part of its 2022 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). A total of 382,518 shares were awarded, with varying vesting schedules. The company continues to focus on developing next-generation antibody-drug conjugates for challenging cancers, particularly in ongoing clinical studies.
Read more →PYXS▲ +13.8%on this news
Pyxis Oncology to Participate in September Investor and Industry Conferences
Pyxis Oncology, Inc. has announced that its President and CEO, Dr. Lara S. Sullivan, will participate in three upcoming investor and industry conferences in September 2025. These include the Cantor Global Healthcare Conference, H.C. Wainwright 27th Annual Global Investment Conference, and the 2nd Annual ADC and Novel Conjugates Summit, where the company will present its ongoing work in antibody-drug conjugates for challenging cancers. The events underscore Pyxis' commitment to investor relations and the advancement of its therapeutic developments.
Read more →PYXS▲ +5.6%on this news
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update • Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous
Pyxis Oncology reported its financial results for Q2 2025, highlighting significant progress in its clinical trials, particularly the monotherapy expansion and combination study of MICVO. The company received a milestone payment of $2.8 million linked to the approval of suvemcitug in China. Despite a reported net loss of $18.4 million, Pyxis anticipates a cash runway sufficient to support operations until the second half of 2026. Overall, the development of their lead candidate MICVO shows promising prospects for addressing the needs in treating recurrent and metastatic head and neck squamous cell carcinoma.
Read more →PYXSPyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update - Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, former
Pyxis Oncology (PYXS) issued its first quarter 2025 financial results, highlighting significant progress with its lead candidate, micvotabart pelidotin (MICVO). The company announced promising preclinical data supporting MICVO's three-pronged mechanism of action. It is on track to report preliminary data from ongoing Phase 1 trials targeting recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in late 2025 and early 2026. Despite an increase in net loss, Pyxis anticipates sufficient cash to fund operations through the second half of 2026.
Read more →PYXS▼ -10.1%on this newsshared move
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
Pyxis Oncology, Inc. will participate in two upcoming investor conferences, presenting insights into its clinical-stage developments. The first event is the 2025 RBC Capital Markets Global Healthcare Conference on May 21, followed by the Jefferies Global Healthcare Conference on June 5. CEO Dr. Lara S. Sullivan will lead fireside chats and have one-on-one meetings with investors. The company's lead candidate, MICVO, is currently in Phase 1 studies aimed at treating recurrent and metastatic head and neck squamous cell carcinoma.
Read more →PYXSPyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
Pyxis Oncology presented robust preclinical results supporting the efficacy of micvotabart pelidotin (MICVO), an antibody-drug conjugate targeting EDB+FN. The studies demonstrated significant anti-tumor activity across various solid tumor types and highlighted a unique three-pronged mechanism of action. Additionally, the combination of MICVO with anti-PD-1 therapy showed improved tumor clearance and durability of immune response. These findings were shared at the AACR Annual Meeting 2025, emphasizing the potential clinical applications of MICVO in treating advanced cancers.
Read more →PYXS▲ +11.5%on this news
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Pyxis Oncology, Inc. announced that its President and CEO, Dr. Lara S. Sullivan, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on April 9, 2025. The event will also feature one-on-one investor meetings. Pyxis is known for developing next-generation therapeutics for challenging cancers, with its lead candidate MICVO undergoing Phase 1 clinical studies focused on recurrent and metastatic head and neck squamous cell carcinoma. A live webcast of the chat will be accessible on the company's investor relations website.
Read more →PYXSPyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
Pyxis Oncology announced it will present new preclinical data on micvotabart pelidotin (MICVO), an ADC targeting EDB+FN, at the AACR Annual Meeting 2025. The data suggests an innovative mechanism of action and potential efficacy, particularly in recurrent and metastatic head and neck squamous cell carcinoma. Additionally, the company is advancing MICVO into clinical trials both as a monotherapy and in combination with Merck’s Keytruda. Preliminary data for these trials is expected between late 2025 and early 2026.
Read more →PYXS▼ -8.6%on this news
Forward Looking Statement This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws.
PYXS has outlined its forward-looking statements relating to the development of its product candidate, micvotabart pelidotin (formerly PYX-201), targeting recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The company emphasizes its differentiated technology and the strong financial position expected to support ongoing clinical trials. However, it acknowledges the risks associated with drug development and reliance on third-party collaborators, which could affect future performance. The company aims to address significant unmet needs in the HNSCC treatment landscape, particularly in patients with difficult-to-treat forms of the disease.
Read more →PYXS▼ -8.6%on this news
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“M
Pyxis Oncology recently announced positive preliminary data from its Phase 1 trial of micvotabart pelidotin, showing a 50% objective response rate in patients with recurrent and metastatic head and neck squamous cell carcinoma. The company received Fast Track Designation from the FDA, enhancing the development prospects of micvotabart. Operational changes include a workforce reduction of approximately 20% and a strategic refocus on advancing its lead therapeutic candidate. Despite a recorded impairment loss, the firm has sufficient cash flow to sustain operations until mid-2026.
Read more →PYXS▼ -6.7%on this news
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
Pyxis Oncology, Inc. has announced its participation in the Leerink Partners Global Healthcare Conference on March 10, 2025, where CEO Dr. Lara S. Sullivan will engage in a fireside chat. The company specializes in developing innovative therapeutics aimed at difficult-to-treat cancers, including its investigational drug PYX-201, currently under Phase 1 clinical study for solid tumors. The event will be accessible via a live webcast and replay on the company's Investor Relations website.
Read more →PYXS▼ -5.8%on this newsshared move
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer Designation applies to the treatment of adult patients with recurrent or metastatic
Pyxis Oncology has received FDA Fast Track Designation for its drug PYX-201, aimed at treating adult patients with recurrent or metastatic head and neck squamous cell carcinoma who have not responded to previous therapies. This designation can expedite the drug’s development and review process, highlighting its potential to meet a critical medical need in this patient population. PYX-201 works by targeting Extradomain-B Fibronectin, a component of the tumor microenvironment, and is currently being evaluated in clinical trials as both a monotherapy and in combination therapies.
Read more →PYXSPyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial • Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradom
Pyxis Oncology has initiated a new Phase 1/2 combination trial for its investigational drug PYX-201 in conjunction with Merck's KEYTRUDA, targeting various solid tumors including recurrent/metastatic head and neck squamous cell carcinoma. Additionally, the ongoing monotherapy trial for PYX-201 has expanded its cohorts to include patients who have received prior treatments. This dual approach represents a strategic move to enhance therapeutic options for patients with limited treatment alternatives. The combination trial is set to start dosing patients in Q1 2025, with optimism surrounding the potential efficacy of PYX-201 in complex cancer scenarios.
Read more →PYXSPyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 - The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept an
Pyxis Oncology has announced a strategic portfolio prioritization to concentrate resources on its lead clinical program, PYX-201, a novel antibody-drug conjugate. PYX-201 has demonstrated significant efficacy in treating head and neck squamous cell carcinoma, with a confirmed objective response rate of 50% in preliminary Phase 1 trial results, supporting further development in multiple solid tumor types. While the company has deprioritized its second clinical program, PYX-106, it anticipates that its current cash runway will fund ongoing trials of PYX-201 into the second half of 2026.
Read more →PYXS▼ -8.2%on this news· ran to -55% by day 3
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
Pyxis Oncology announced promising preliminary data from its Phase 1 clinical study of PYX-201, an antibody-drug conjugate targeting difficult-to-treat cancers. The drug demonstrated a confirmed 50% objective response rate in heavily pretreated head and neck cancer (HNSCC) patients. Additionally, a collaboration with Merck was established to study PYX-201 in combination with KEYTRUDA in patients with various tumor types. The treatment has shown a favorable safety profile, reinforcing its potential for further development in both monotherapy and combination settings.
Read more →PYXS▼ -8.2%on this news· ran to -55% by day 3
PYX-201 Phase 1 Dose Escalation Study Data Disclosure November 2024 Forward Looking Statement This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securit
The article discusses the recent Phase 1 dose escalation study data for PYX-201, a novel antibody-drug conjugate by Pyxis Oncology. PYX-201 targets EDB+FN, an extracellular matrix component, and has demonstrated a 26% overall response rate in several solid tumors. The treatment exhibits favorable safety and tolerability, making it a candidate for combination therapies with KEYTRUDA. However, the presentation also highlights the inherent risks in the clinical development process and the uncertainties surrounding future results.
Read more →PYXSPyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024 - Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and
Pyxis Oncology reported its financial results for Q3 2024 and discussed preliminary data from its ongoing Phase 1 trials for PYX-201 and PYX-106. The company has a substantial cash reserve of $146.3 million, which is projected to fund operations into the second half of 2026. Preliminary results from the trials are set to be presented at an investor event in New York City on November 20, 2024. Despite promising developments, the company reported a net loss of $21.2 million for the quarter, raising questions about its financial stability moving forward.
Read more →PYXS▲ +7.2%on this newsshared move
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
Pyxis Oncology, Inc. has announced an upcoming investor event to present preliminary data from the Phase 1 trial of its lead drug candidate PYX-201, focusing on targeting difficult-to-treat solid tumors. The event will take place both in-person in New York City and virtually on November 20, 2024. Renowned physician leaders will join the executive team to discuss insights from about 80 patients involved in the trial. The presentation will cover safety, preliminary efficacy, and pharmacokinetics, marking a significant step in the drug's development process.
Read more →PYXSPyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024 - Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data
Pyxis Oncology has announced its second quarter financial results and provided updates on its clinical trials. The company reported a cash balance of $157.2 million, which is projected to sustain operations into the second half of 2026. Preliminary data from its Phase 1 trial of the therapeutic candidate PYX-201 is expected to be disclosed in the fall of 2024. Meanwhile, the company has also initiated trials for PYX-106, with results anticipated by year-end 2024. Despite a net loss of $17.3 million for the quarter, other metrics indicate ongoing operational momentum.
Read more →PYXSPyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
Pyxis Oncology, Inc. (Nasdaq: PYXS) will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference on August 5-6, 2024. Lara S. Sullivan, M.D., the company's President and CEO, along with other management members, will engage with investors during the event. The company is focused on advancing next-generation therapeutics aimed at challenging cancer types. This participation indicates a proactive approach in investor relations amidst their clinical developments.
Read more →PYXSPyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
Pyxis Oncology announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. With over 25 years of experience in the biopharmaceutical sector, Metzger's expertise is expected to contribute significantly to the company's growth and mission of targeting difficult-to-treat cancers. Pyxis is recognized for its innovative antibody-drug conjugate therapies and has a promising pipeline in clinical stages. Metzger aims to leverage his knowledge to advance the company's objectives and improve patient outcomes.
Read more →PYXSPyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
Pyxis Oncology, Inc. (NASDAQ: PYXS) will have its CEO Lara S. Sullivan participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024. This event will take place at 9:00 AM Eastern Time in New York City and includes opportunities for investor one-on-one meetings. The presentation will be available for live streaming and replay on the company's Investor Relations website, enhancing accessibility.
Read more →PYXSPyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
Pyxis Oncology reported positive financial results for Q1 2024, with cash reserves expected to sustain operations through 2026. The company continues to advance its clinical trials for PYX-201 and PYX-106, aiming for key data releases in fall 2024 and 2H 2024, respectively. The appointment of Stephen Worsley as Chief Business Officer signals a strategic move to strengthen leadership and business development efforts.
Read more →PYXS▲ +5.6%on this newsshared move
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
Pyxis Oncology, Inc. has announced that its CEO, Dr. Lara S. Sullivan, will be participating in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 14, 2024. The event will provide an opportunity for management to engage directly with investors through one-on-one meetings. Additionally, a live webcast of the presentation will be available for those unable to attend. This showcases the company's ongoing efforts to connect with its investor base and communicate its strategic vision.
Read more →PYXS▲ +9.7%on this news· ran to +40% by day 3shared move
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The Merger On
On August 23, 2023, Pyxis Oncology, Inc. completed its acquisition of Apexigen, making Apexigen a wholly owned subsidiary. The merger is reflected in unaudited pro forma financial statements intended to demonstrate its financial impact as if it had been finalized at the beginning of 2023. The agreement included the issuance of 4,344,435 shares of Pyxis common stock to Apexigen shareholders. However, the pro forma data serves illustrative purposes and may not predict actual future financial outcomes.
Read more →PYXS▲ +9.7%on this news· ran to +40% by day 3shared move
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
Pyxis Oncology has successfully sold its royalty rights for Beovu and another asset to Novartis, receiving $8 million in a one-time cash payment. This funding will support the development of its lead asset, PYX-201, an Antibody-Drug Conjugate. In addition, Pyxis retains rights to three other antibodies from Apexigen's developmental pipeline, adding potential for future earnings. The payment underscores Pyxis's strengthening financial position as it continues to focus on difficult-to-treat cancers.
Read more →PYXS▼ -8.7%on this news· ran to -29% by day 3
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
Pyxis Oncology provided a corporate update and reported its financial results for the fourth quarter and full year of 2023. The company is progressing with its Phase 1 trials of PYX-201 and PYX-106, with preliminary data expected in 2024. Pyxis successfully raised $50 million through a private placement, ensuring a cash runway until the second half of 2026. The company reported a net loss of $73.8 million for the year while lowering its operating expenses compared to the previous year.
Read more →PYXS▼ -6.1%on this news· ran to -17% by day 1
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
Pyxis Oncology has appointed Santhosh Palani, Ph.D., CFA, to its Board of Directors, effective March 12, 2024. Dr. Palani brings over a decade of experience in drug development and strategic expertise within the biopharma industry. His appointment is expected to enhance the leadership team as the company anticipates data readouts for its lead asset, PYX-201, in 2024. The addition of Dr. Palani aims to drive future growth and collaboration within the company.
Read more →PYXSPyxis Oncology to Present at Leerink Global Biopharma Conference 2024
Pyxis Oncology, Inc. announced that CEO Lara S. Sullivan will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on March 13, 2024. The event will take place in Miami Beach, Florida, and include investor one-on-one meetings. A live webcast of the presentation will be available through the company's Investor Relations page, highlighting their ongoing efforts in developing therapeutics for difficult-to-treat cancers.
Read more →PYXSPyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
Pyxis Oncology has announced that it will present new preclinical data on its therapeutic candidates PYX-201, PYX-106, and PYX-102 at the AACR Annual Meeting in April 2024. Notably, the data for PYX-201 indicates strong anti-tumor efficacy across various human cancer indications, thanks to its targeting of the EDB+FN protein. The efficacy of PYX-106 and PYX-102 was also highlighted, suggesting promising clinical opportunities. The posters will be made accessible on the company's website following the presentations at the conference.
Read more →PYXS▲ +33.3%on this news
Pyxis Oncology Announces $50 Million Private Placement
Pyxis Oncology, Inc. has announced a private placement deal that will raise approximately $50 million through the sale of 8,849,371 shares of common stock at $4.78 each, alongside pre-funded warrants. The private placement, led by institutional investors, is expected to close on or about February 29, 2024. The net proceeds will be utilized for the continued development of the company's lead therapeutic candidate, PYX-201, which is undergoing a Phase 1 study targeting solid tumors. This financing highlights investor confidence in Pyxis's approach to treating difficult cancers.
Read more →PYXSPyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
Pyxis Oncology, Inc. has appointed Dr. Ken Kobayashi as Chief Medical Officer, effective November 27, 2023. Dr. Kobayashi brings over 25 years of experience in oncology drug development, including a strong track record with antibody-drug conjugates and other modalities. As CMO, he will oversee clinical and regulatory operations, while also driving strategic growth and advancing Pyxis Oncology's clinical pipeline. His expertise is expected to significantly contribute to the development of innovative therapies for challenging cancer types.
Read more →PYXSPyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
Pyxis Oncology reported financial results for the third quarter of 2023, announcing initiatives to prioritize its lead ADC program, PYX-201, which is currently in a Phase 1 trial with data expected in the first half of 2024. The company's cash runway has been extended to early 2026 due to significant cost reductions and strategic portfolio adjustments. Additionally, a reduction in workforce by 40% was announced as part of measures to improve financial discipline, while focusing on advancing both PYX-201 and PYX-106 programs.
Read more →PYXSPyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
Pyxis Oncology, Inc. announced that four abstracts related to its different therapeutic assets have been accepted for presentation at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting scheduled for November 1-5, 2023. The company will showcase a trial-in-progress poster for its first-in-class tumor stroma-targeting antibody-drug conjugate, PYX-201, expected to show promising data in early 2024. Also highlighted are advancements in other candidates including PYX-106 and a newly acquired CD40 agonist, demonstrating the company’s commitment to innovating cancer therapies.
Read more →PYXSPyxis Oncology to Participate in Two Upcoming Investment Conferences
Pyxis Oncology, Inc. (Nasdaq: PYXS) announced its participation in two investment conferences scheduled for September 2023. Members of the executive team will conduct in-person 1x1 meetings during the Wells Fargo Healthcare Conference, and a pre-recorded presentation by the CEO will be available at the H.C. Wainwright Annual Global Investment Conference. These events signal Pyxis's commitment to increasing investor relations and showcasing its developments in cancer therapeutics.
Read more →PYXSPyxis Oncology Successfully Completes Acquisition of Apexigen
Pyxis Oncology has successfully completed the acquisition of Apexigen in a transaction valued at approximately $10.7 million. This acquisition enhances Pyxis's capabilities in developing antibody-drug conjugates (ADCs) and expands its pipeline with the addition of the Phase 2 candidate sotigalimab, now designated PYX-107. The company maintains a cash runway into the first half of 2025 to evaluate early signs of clinical activity. Leadership remains the same, with notable additions to the board, including industry expert Jakob Dupont.
Read more →PYXS▲ +6.6%on this news
Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update Third dose cohort initiated in Phase 1 trial of PYX-201, Pyxis Oncology's first ADC product candidate Preliminary data from t
Pyxis Oncology reported its financial results for Q2 2023, highlighting a strong cash position of $144.1 million which supports operations into the first half of 2025. The company initiated a third dose cohort in its Phase 1 trial of PYX-201 and expects to present preliminary data from ongoing trials by late 2023 and early 2024. Additionally, the anticipated acquisition of Apexigen is expected to close later this month, which will enhance Pyxis's capabilities in antibody-drug conjugate innovation. Despite a net loss of $15.9 million for the quarter, Pyxis remains optimistic about its clinical advancements.
Read more →PYXSPyxis Oncology to Present at BTIG Virtual Biotechnology Conference
Pyxis Oncology, Inc. announced that its President and CEO, Lara S. Sullivan, will present an overview of the company at the BTIG Virtual Biotechnology Conference on August 7, 2023. The presentation aims to provide insights into Pyxis's efforts in developing therapeutics for challenging cancers. Additionally, the company's management team will conduct investor meetings on the same day, highlighting its commitment to investor relations and transparency. This event aligns with Pyxis's strategic focus on innovation in cancer treatment.
Read more →PYXSPyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
Pyxis Oncology has advanced its clinical programs for two candidates: PYX-106 and PYX-201. The first subject has been dosed in a Phase 1 trial for PYX-106, a fully human immunotherapy designed to block the immune suppressor Siglec-15. Additionally, the second dose level for PYX-201, an antibody-drug conjugate targeting extradomain-B of fibronectin, has been initiated in its Phase 1 trial. The company anticipates preliminary data from both trials by late 2023 or early 2024.
Read more →PYXS▼ -10.5%on this newsshared move
Pyxis Oncology to Acquire Apexigen
Pyxis Oncology announced the acquisition of Apexigen in an all-stock deal valued at $16 million, allowing it to bolster its antibody-drug conjugate (ADC) capabilities. The acquisition is expected to enhance Pyxis's clinical pipeline, particularly with the promising CD40 agonist Sotigalimab. This strategic move maintains the company's cash runway into the first half of 2025. However, the merger is subject to approval from Apexigen's stockholders and customary closing conditions.
Read more →PYXS▼ -10.5%on this newsshared move
Pyxis Oncology to Acquire Apexigen Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC t
Pyxis Oncology announced its acquisition of Apexigen in an all-stock transaction valued at approximately $16 million. This strategic move will integrate Apexigen's APXiMAB platform into Pyxis's existing therapeutic framework, aimed at advancing next-generation antibody-drug conjugates (ADCs). The acquisition is expected to bolster the clinical pipeline of Pyxis Oncology, particularly with the promising potential of the CD40 agonist, Sotigalimab, which has demonstrated strong anti-cancer activity in various challenging tumor types. Overall, the merger is poised to enhance the capabilities of both companies in oncology therapeutics.
Read more →PYXS▼ -10.5%on this newsshared move
This presentation contains forward looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than
Pyxis Oncology has presented forward-looking statements regarding its acquisition of Apexigen, highlighting expectations about future operations and financial performance. The predictions, however, come with significant risks and uncertainties, including potential regulatory hurdles and the need for shareholder approval. The company emphasizes that actual results may vary considerably from those forecasted. The presentation urges stakeholders to consider the various factors that could affect the transaction.
Read more →PYXSPyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update Orphan Drug Designation received for PYX-201 in pancreatic cancer Preliminary data from two Phase 1 trials anticipated lat
Pyxis Oncology, Inc. reported financial results for the first quarter of 2023, highlighting its transition to a clinical-stage company with two ongoing Phase 1 trials. The company secured Orphan Drug Designation for PYX-201 in pancreatic cancer. With $150.8 million in cash, sufficient to fund operations into 2025, Pyxis anticipates preliminary trial data by late 2023 to early 2024. Despite a reduced net loss compared to the previous year, operational expenses remain a concern for the company.
Read more →PYXSPyxis Oncology Reports Financial Results for the Fiscal Year Ended
Pyxis Oncology, Inc. reported financial results for the fiscal year ended December 31, 2022, alongside a corporate update. The company has initiated two Phase 1 clinical trials for its drug candidates PYX-106 and PYX-201, with preliminary data expected in late 2023 to early 2024. As of year-end 2022, Pyxis had a strong financial position with $180.7 million in cash and no debt, providing a runway into the first half of 2025.
Read more →PYXS▲ +7.5%on this news· ran to +37% by day 1
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early 20
Pyxis Oncology has initiated its first Phase 1 clinical trial for PYX-201, a novel antibody-drug conjugate designed to target solid tumors by binding to EDB fibronectin. This marks a significant milestone in their transition to a clinical-stage company, with preliminary data expected in early 2024. The trial aims to evaluate the safety and efficacy of PYX-201 in patients with relapsed or refractory solid tumors. Experts are optimistic about the drug's potential to improve safety and efficacy over traditional ADCs.
Read more →PYXSPyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference
Pyxis Oncology, Inc. is set to participate in the upcoming SVB Securities Global Biopharma Conference on February 15, 2023. The company's top executives, including Dr. Lara Sullivan and Dr. Jay Feingold, will host meetings with institutional investors, presenting an opportunity to discuss the firm's developments in targeting difficult-to-treat cancers. This involvement underscores Pyxis's commitment to investor engagement and collaboration within the biopharma community.
Read more →PYXSPyxis Oncology Announces FDA Clearance of Two IND Applications FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate Phase 1 clinic
Pyxis Oncology Announces FDA Clearance of Two IND Applications FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate Phase 1 clinical trials of PYX-201 and PYX-106 will evaluate the safety
Read more →PYXS▼ -9.6%on this news
Pyxis Oncology Reports Financial Results for the Quarter Ended
Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update -Expands worldwide licensing agreement with Pfizer to obtain additional antibody-drug conjugate (ADC) platform components -Gains exclusive rights to Pfizer's ADC tech
Read more →PYXSPyxis Oncology Reports Financial Results for the Second Quarter Ended
Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update -Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities -Appointed Rachel Humph
Read more →PYXSPyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference
CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, today announced that the Company will present at the H.C. Wainwright Preclinical Cancer
Read more →PYXSPyxis Oncology Announces Presentations at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive
Read more →PYXSPyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executiv
Read more →PYXSPyxis Oncology Announces Leadership Changes
Pyxis Oncology Announces Leadership Changes - Ronald Herbst, Ph.D., stepping down as Chief Scientific Officer - - Jan Pinkas, Ph.D., promoted to Chief Scientific Officer - - Company continues to advance programs toward the clinic with IND filings for Anti-EDB, PYX-201, and
Read more →PYXSPyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting
- Data highlight PYX-106’s differentiated activity profile and antitumor activity in an in vivo mouse model - - Preclinical data support IND filing in 2H 2022 - CAMBRIDGE, Mass. and NEWARK, Del. and NANJING, China, April 08, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq
Read more →PYXSPyxis Oncology Provides Corporate and Financial Update Announces Expansion of Novel Immuno-Oncology Therapeutic Portfolio with Addition of Anti-Siglec-15 In-licensed from Biosion (PYX-106) Introduces First Internally Dev
Pyxis Oncology Provides Corporate and Financial Update Announces Expansion of Novel Immuno-Oncology Therapeutic Portfolio with Addition of Anti-Siglec-15 In-licensed from Biosion (PYX-106) Introduces First Internally Developed IO Candidate Anti-KLRG1 (PYX-102) Cash Runway Suff
Read more →PYXS▼ -8%on this news
Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022
CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset, multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced it will host a conference call and live webcast on Tu
Read more →PYXSPyxis to be Added to Russell 2000 Index
CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that the company will be added to the Russell 2000® Index, ef
Read more →PYXSPyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer
CAMBRIDGE, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced the appointment of Martina Molsbergen as Interim Chief Business Officer. Ms. Molsbergen will be responsible for managing the Company’s current partnerships and joint ventures a
Read more →PYXSPyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update
Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to tre
Read more →PYXSPyxis Oncology to Present at the Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), today announced that management will present at and host one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 20
Read more →PYXSPyxis Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients, today announced
Read more →PYXSPyxis Oncology Appoints Jay M. Feingold, M.D., Ph.D., as Chief Medical Officer
CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the “Company”) today announced the appointment of Jay M. Feingold, M.D., Ph.D., as Chief Medical Officer. “Jay’s track record of success taking oncology ADC programs from discovery to commercial laun
Read more →PYXSPyxis Oncology Strengthens Board of Directors
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the “Company”) today announced the appointments of Freda Lewis-Hall, M.D., Thomas Civik, Darren Cline, and Mark Chin to its Board of Directors. These strategic appointments strengthen the company’s op
Read more →PYXSPyxis Oncology Appoints Pamela Yanchik Connealy as Chief Financial Officer
CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the “Company”) today announced the recent appointment of Pamela Yanchik Connealy, M.B.A., as its Chief Financial Officer. Ms. Connealy will be leading the Finance, Investor Relations and Human Resource
Read more →PYXSPyxis Oncology Strengthens Leadership Team with Executive and Scientific Advisory Board Appointments
– Steve Monks, Ph.D., appointed as Chief Technical Officer, brings 20+ years in drug development and CMC, Quality, and Regulatory operations – – Ritu Shah, PMP, appointed as Chief Operating Officer, brings 20+ years of industry experience specializing in portfolio management and
Read more →PYXSPyxis Oncology Presents Preclinical Data and Details on Antibody-Drug Conjugate Candidates Supporting Therapeutic Potential
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the "Company") today announced the targets of its three antibody-drug conjugate (ADC) candidates along with additional details and preclinical data supporting the potential of its ADC platform. The Co
Read more →PYXSPyxis Oncology Hosting Key Opinion Webinar on Antibody-Drug Conjugates
CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the "Company") today announced that it will host a key opinion leader (KOL) webinar on antibody-drug conjugates on Tuesday, April 27, 2021 at 1pm Eastern Time. The webinar will feature presentations
Read more →PYXSPyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics
-- New round enables Pyxis to advance differentiated antibody-drug conjugate (ADC) and immuno-oncology (I/O) programs to next value inflection point -- -- In addition to recently announced in-licensed ADC candidates and ADC toolkit from Pfizer, funding to support in-licensed ADC
Read more →PYXSPyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology (“Pyxis” or the "Company”) today announced that it has entered into a worldwide license agreement with Pfizer Inc. (NYSE:PFE) for the development and commercialization of two antibody-drug conjugate (ADC) candida
Read more →Competitive Position
How PYXS ranks across every disease it competes inCompetitive Position is a premium feature
See how PYXS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial